New Evidence for Homocysteine Lowering for Management of Treatment-Resistant Hypertension

Abstract

Reembracing the label H-hypertension, with renewed attention on homocysteine pathophysiology and more nuanced homocysteine reference intervals will clarify the urrent confusion. Lowering homocysteine and hypertension do not always require dangerous or expensive drugs. Addressing how C677T riboflavin insensitivity leads to l-methylfolate depletion, homocysteine elevation, and resistant hypertension, points to an elegant and safe opportunity for attacking stubbornly resistant hypertension ultimately improving neurological and cardiovascular outcomes.3,4,19 A significant literature indicates that supplements with sufficient nondietary sourced vitamins B2 (riboflavin), B6, reduced folate, and B12 can blood pressure as much as 6–13 mm Hg. Utilizing riboflavin and folate is a safe and economical therapy for reduction of hypertension and stroke.3,4,19 The goal is successful management of treatment-resistant hypertension and safely reducing its consequential end organ damage to hearts, brains, and vision. It is time for action.